Export

EN
FR
Artemether
Essential medicine status
Section:
6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.1. Antimalarial medicines > Medicines for curative treatment
ATC codes: P01BE02
EMLc
Indication
Malaria due to Plasmodium vivax ICD11 code: 1F81
INN
Artemether
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Additional notes
For use in the management of severe malaria
Formulations
Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection) ; 40 mg per mL in 1 mL ampoule (oily injection)
EML status history
First added in 1997 (TRS 882)
Changed in 2002 (TRS 914)
Changed in 2007 (TRS 946)
Changed in 2007 (TRS 950)
Changed in 2025 (TRS 1064)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Artemether
DrugBank
Artemether
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended replacing the 80 mg/mL strength of artemether oily injection with 20 mg/mL and 40 mg/mL strengths. The 80 mg/mL strength has limited utility for children under 12 years of age.